All Pennsylvania residents ages 5 and older are eligible for the COVID-19 vaccine. Primary Health Network is administering the Moderna vaccine for those 18+, and the Pfizer vaccine for children ages 5-11.
Due to required pre-screening, online scheduling is not available for COVID-19 booster shots or third doses. Clarification on eligibility criteria can be found below in the Vaccine Scheduling FAQs section.
Those who are 50 years of age or older or those 18 years of age with certain kinds of immunocompromise may receive a second booster dose at least 4 months after the first booster dose.
To schedule your COVID-19 booster shot or the COVID-19 third dose, please call our COVID Specialists directly at 724-699-9211, option 1.
Online scheduling is available below for all COVID-19 primary vaccination series (first and second shots). Primary Health Network offers the Moderna COVID-19 vaccine, which is only authorized for those 18 years of age and over, and the Pfizer COVID-19 vaccine for children ages 5 through 11 years.
Currently, the Pfizer vaccine is only available at our Sharon Medical Group location. When scheduling, please select Sharon Medical Group Primary Care>COVID Vaccine Clinic Second Floor>Pfizer.
For individuals completing their primary series with the mRNA vaccine, they should expect to receive two doses of the same product.
Yes. The U.S. vaccine safety system ensures that all vaccines are as safe as possible. The COVID-19 vaccine has been held to the same rigorous safety and efficiency standards as all other types of vaccines.
COVID-19 vaccines are effective at protecting people from COVID-19 and help keep adults and children from getting seriously sick. They can also reduce the risk of people spreading the virus that causes COVID-19.
Although COVID-19 vaccine and boosters are not formulated to target specific COVID-19 variants, they do improve protection. In other words, the boosters increase neutralizing antibodies against the concerning variants such as Delta and the newly discovered, Omicron variant.
The side effects from COVID-19 vaccination may feel like flu and might even affect your ability to do daily activities, but they should go away in a few days. This is a normal sign that your body is building protection.
Allergic reactions were uncommon during COVID-19 vaccine trials. However, all recipients receiving the vaccine, are required to be monitored for at least 15 minutes after vaccination for any possible reactions. If you have a history of allergic reactions to vaccines, please talk to your healthcare provider before receiving a COVID-19 vaccine.
Yes. The COVID-19 vaccine is recommended for people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future.
People who are pregnant may also receive a COVID-19 vaccine booster shot.
Based on the recommendation from the CDC, those who have had COVID-19 should still receive the vaccine. If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine.
No. The COVID-19 vaccines currently being developed in the U.S. don't use the live virus that causes COVID-19.
At Primary Health Network, we are offering the Moderna vaccine for those 18+, and the Pfizer vaccine for children ages 5-11.
Two doses are required. When we call to schedule your first vaccine with us, we will also schedule you for your second dose. You must receive the second dose 26-30 days after the first dose.
Yes. You may either schedule online or call 724-699-9211, option 1.
For individuals completing their primary series with mRNA vaccine, they should receive two doses of the same product. Once they’ve completed their primary series and if they’re eligible for a booster dose, they may receive any one of the three available products.
It is important to note that those who have received one shot of the J & J vaccine are considered fully vaccinated. A single booster dose may be given no sooner than 2 months after the single dose of J & J. According to the current Emergency Use Authorization criteria, no additional booster doses would be appropriate afterwards.
A pre-visit registration will be sent to you directly via text message or email one day prior to your appoi ntment. Please be sure to complete the patient pre-visit registration to ensure timely access to your appointment. Along with the pre-visit check-in, we ask that you also bring the following items with you on the day of your appointment:
Yes. COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day.
Yes, PHN is currently offering booster doses of the Moderna COVID-19 vaccine.
The CDC recommends a COVID-19 booster if you are:
Yes, PHN will offer the third dose to those considered to be immunocompromised.
The CDC and the FDA recommend an additional dose for those who are immunocompromised and ages 5 and older. This includes those who:
There is no cost to receive the COVID-19 vaccine. If you have insurance, we will bill an administration fee to your insurance company. However, this does not result in any out of pocket cost for you.
The third dose is exactly that - an additional dose of the vaccine for some immunocompromised individuals to help them generate a stronger immune response similar to what most people get with just two doses.
A booster dose is given to people whose immune response has weakened over time. According to the CDC, immunity from some vaccines can wear off, and at that time, a booster dose would be required. The dosage may be different than what people first received.
Primary Health Network is providing drive-up and on-site testing for those suspected of having COVID-19 at select locations throughout our Network. Patients are required to be evaluated by a PHN provider through a telehealth appointment to determine if testing is necessary. Patients who meet the criteria for COVID-19 testing will be given an appointment and directed to a testing location.
For more information or to schedule an appointment, please call 724-699-9211, option 1.
COVID-19 tests are available at no cost nationwide. The only cost to the patient is for the initial evaluation. As a Community Health Center, PHN accepts all patients regardless of insurance status or ability to pay. We participate in most managed care plans, process most insurances, and offer a Sliding Fee Scale to eligible patients for discounted services.
Fighting COVID-19 continues to be a top priority in medical research and pharmaceutical development. Treatment for COVID-19 depends on the severity of the infection. However, recent therapeutic advancements have proven to reduce the spread of COVID-19 and prevent further infections.
At Primary Health Network, we are offering dispensing of COVID-19 Oral Antiviral Molnupiravir at 6 of our rural locations:
Scheduling Molnupiravir pick up time and location
Please have your family physician fax to us the date of symptom onset, which must be within the past 5 days of a positive COVID-19 test, a negative pregnancy test, or other reliable method of contraception, and a prescription for Molnupiravir.
Fax to us at 724-308-5722
For more information on the scheduling process, you can contact us at 724-699-9211, option 1.
Molnupiravir is used for the treatment of mild-to-moderate COVID-19 in adults (18 years of age), who:
High risk reasons for more serious symptoms include:
Talk with a healthcare provider to determine if molnupiravir is appropriate treatment option for you. If it is determined that you would benefit from one of these treatments, the healthcare provider will write you a prescription for the appropriate medication.
Molnupiravir is administered as 4 capsules every 12 hours for 5 days. It is important that patients complete the full 5 days of treatment with molnupiravir, even if they feel better.
Common side effects of molnupiravir are diarrhea, nausea, and dizziness.
Primary Health Network is one of the few healthcare organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.
This one-time administration may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.
Due to limited supply, those eligible for this treatment must meet the following criteria:
For more information on eligibility or to schedule your treatment, please call 724-977-6370.
GSK's sotrovimab is administered through a one-time intravenous (IV) infusion. The infusion takes about one hour to complete, and you must stay at the infusion center for another hour to be monitored for allergic reactions or other side effects.
Allergic reactions can occur during and after infusion with this treatment. Tell your healthcare provider right away if you experience any of the following signs and symptoms of allergic reactions: fever; chills; nausea; headache; shortness of breath; low blood pressure; wheezing; swelling of your lips, face, or throat; rash, including hives; itching; muscle aches; and/or dizziness.
An infusion of any medicine may cause brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
Potential side effects of sotrovimab include anaphylaxis (anaphylactic shock), and infusion-related reactions, rash and diarrhea.
These are not all the possible side effects of treatment. Serious and unexpected side effects may happen.
Even if you start feeling better, you could still spread the virus. Isolate at home until all the following occur:
Check with your insurance provider to determine the cost of treatment.
Yes, you are eligible for treatment if you received one or more doses of a COVID-19 vaccine.
You should not be vaccinated for COVID-19 within 90 days of treatment.
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab). Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination.
In immunocompromised patients, a vaccination may not generate enough immune response, so they are still vulnerable to severe infection. Evusheld gives additional immunity to help prevent COVID-19.
Evusheld is a combination of two monoclonal antibodies given in two consecutive injections in the arm, in one visit, to qualifying patients who do not have COVID-19. Patients will be monitored for one hour afterward for any side effects.
The current FDA has given an EUA for this medicine to be given to those with specific illness or medical situations which puts them at high-risk of developing severe COVID-19 illness.
Adults and pediatric individuals (12 years of age and older weighing at least 40 kg):
PrEP medicines are designed to proactively protect certain individuals from COVID-19 infection prior to exposure. These medicines use monoclonal antibodies (laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens) to block the COVID-19 virus' attachment and entry into human cells.
In the United States, AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab and administered together) is the only product currently authorized for pre-exposure prevention.
Evusheld is only authorized for adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) who are not currently infected with COVID-19 virus and who have not recently been exposed to an individual infected with COVID-19. The authorization also requires that individuals either: have moderate to severely compromised immune systems and may not mount an adequate immune response to COVID-19; or are recommended to not receive vaccination against COVID-19.
Possible side effects of Evusheld include: allergic reactions (including anaphylaxis), cardiac events, bleeding at the injection site, headache, fatigue and cough.
You should talk with a health care provider to determine whether Evusheld is an appropriate pre-exposure prevention option for you.
To protect our most vulnerable patients, we are limiting the amount of visitors to 1 per adult patient. For pediatric patients, we ask that parents and guardians bring ONLY the child seeking care to the office visit. Only 1 adult will be permitted to attend the visit with the child.
We are discontinuing all public use of our conference and community space, effective immediately, until future notice.
We understand that these restrictions may cause challenges for our patients and their families. Thank you for your patience and adherence to these policies as part of our continued efforts to keep our patients, visitors, and workforce protected and healthy during this time.
If you are experiencing a medical emergency, please call 911 or go to your nearest emergency room.
If you are experiencing a psychiatric emergency, please call 911 or contact the National Suicide Prevention Lifeline 1-800-273-TALK